Correction to: Digestive Diseases and Sciences (2019) 64:1651–1659 https://doi.org/10.1007/s10620-019-05570-1
The original version of the article unfortunately contained a couple of errors. In ‘Methods’ section, ‘Outcomes’ subsection, the sentence ‘Endoscopic remission was defined as an SESCD ≤ 2 in patients with CD and an EMS ≤ 2 in UC patients while off corticosteroids.’ should read ‘Endoscopic remission was defined as an SES-CD ≤ 2 in patients with CD and an EMS ≤ 1 in UC patients while off corticosteroids.’
In Figure 1, legend of light blue coloured bars ‘In Endoscopic Remission at Week 52’ should be replaced with ‘Not in Endoscopic Remission at Week 52’. Corrected version of Fig. 1 is given below.
Differences between vedolizumab levels at several time points among patients that were and were not in remission at week 52 of therapy. Endoscopic remission was defined as mucosal healing, clinical remission, and normal C-reactive protein
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yarur, A.J., Bruss, A., Naik, S. et al. Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases. Dig Dis Sci 64, 3674–3675 (2019). https://doi.org/10.1007/s10620-019-05876-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-019-05876-0